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Abstract Percutaneous coronary intervention (PCI) of
multivessel and/or left main stem disease have been shown
to be potentially legitimate revascularization alternatives in
appropriately selected patients. Risk stratification is an
important component in guiding patients to identify the
most appropriate revascularization modality (PCI or coro-
nary artery bypass grafting [CABG]) in conjunction with
the Heart Team. The aim of this paper is to give the
clinician a concise overview of the important established
and evolving contemporary risk models in aiding this
decision-making process. Risk models, based on clinical
and anatomical variables alone, the novel concept of
functional anatomical risk scores, and risk models combin-
ing aspects from both clinical and anatomical scores, are
all discussed. The emerging concepts of the patient-
empowered risk/benefit tradeoff between PCI and CABG
to help personalize the choice of revascularization
modality are also explored.
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Clinical Trial Acronyms
ARTS Arterial Revascularization Therapies Study
FAME Fractional Flow Reserve V ersus Angiography
for Guiding PCI in Patients with Multivessel
Evaluation
LEADERS Limus Eluted from a Durable V ersus
Erodable Stent Coating
RESEARCH Rapamycin-Eluting Stent Evaluated at
Rotterdam Cardiology Hospital
SYNTAX Synergy Between Percutaneous Coronary
Intervention with TAXUS and Cardiac
Surgery
T-SEARCH Taxus Stent Evaluated at Rotterdam
Cardiology Hospital.
Introduction
Risk stratification is an integral and increasingly important
aspect of the assessment of patients with complex coronary
artery disease who are candidates for coronary revascular-
ization. Although the landmark SYNTAX trial established
that surgery was the standard of care for patients with left
main stem (LMS) and/or multivessel disease, an important
finding from this study was that patients with less complex
disease were found to have equivalent outcomes to surgery
at 1 and 3 years' follow-up [1, 2￿, 3].
The “Heart Team” approach in managing these complex
patients was pioneered within the SYNTAX trial, and has
recently been incorporated as a class I recommendation in
recent myocardial revascularization guidelines [4]. As part
of this approach, risk models to appropriately stratify
patients are crucial to aid in the decision-making process
regarding the choice of revascularization modality. Within
cardiothoracic practice, the use of risk scores are well
established and are predominantly related to clinical
variables alone, with the EuroSCORE (European System
for Cardiac Operative Risk Evaluation) being in widespread
contemporary use [5, 6].
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DOI 10.1007/s11886-011-0202-5With percutaneous coronary intervention (PCI) of com-
plex coronary artery disease, the risk models are still
evolving, with models consisting of clinical or anatomical
variables alone or combinations of the two variable types.
Whereas anatomical variables have been shown to be less
important for surgical outcomes, the SYNTAX trial and
subsequent studies have confirmed these to be of significant
importance for multivessel PCI [7, 8]. However, there is
recognition that both anatomical and clinical variables are
required to appropriately risk stratify patients contemplating
percutaneous revascularization.
The purpose of this review article is to explore the
numerous types of risk scores that are available that take
into account either anatomical or clinical variables alone
or a combination (Table 1). We also aim to highlight areas
of potential further developments of contemporary risk
models—in particular, the emerging concept of a risk/
benefit tradeoff—all of which may ultimately allow the
individual patient and the Heart Team to best determine
the most appropriate revascularization strategy.
Anatomical- and Functional-Based Risk Scores
In 1981, our group developed a coronary scoring system
that assessed the severity and extent of the underlying
coronary artery disease [8]. This system was based on the
severity of luminal diameter narrowing and weighted
according to the usual flow to the left ventricle in each
coronary vessel. Consequently the most weight was given
to the LMS, followed by the left anterior descending,
circumflex, and right coronary arteries. This early pioneer-
ing work ultimately formed the basis of the SYNTAX score
(SXscore) [7, 9]. Since then, numerous angiographic-based
risk scores have been developed (Table 1), several of which
are described below.
American College of Cardiology/American Heart
Association Lesion Classification System
The American College of Cardiology/American Heart
Association (ACC/AHA) lesion classification system was
one of the first angiographic scoring systems developed,
comprising of 11 angiographic variables with all lesions
categorized into types (A, B1, B2, and C) [10]. This system
was predictive of the angiographic success of PCI with a
subsequent prognostic effect on the early and late clinical
outcomes in the pre drug-eluting stent era. However,
registry data from the drug-eluting stent era have had
conflicting results. The German Cypher registry (n=6755)
failed to show any significant association with clinical
outcomes at 6 months [11]; conversely, data from the ARTS
II registry suggested an association with clinical outcomes
for two and three-vessel disease (3VD) [12]. Furthermore, a
small registry (n=255) demonstrated this classification
system to be potentially predictive of mortality in unpro-
tected LMS PCI at 1-year follow-up [13].
SYNTAX Score
The SXscore is a well-described anatomical risk-based
score that takes into account features such as bifurcations,
total occlusions, thrombus, calcification, small vessels, and
so forth. Each coronary lesion with a greater than 50%
luminal obstruction lumen in vessels≥1.5 mm are separately
scored and summated to provide the overall SXscore. This is
calculated using dedicated softwarethatintegratesthe number
of lesions with their specific weighting factors, based on the
amount of myocardium distal to the lesion and morphologic
features of each single lesion [7, 8, 9, 14].
Within the SYNTAX trial, [1] the distribution of the
SXscore was found to be Gaussian in the randomized PCI
and coronary artery bypass grafting (CABG) populations
with the curves almost being superimposable (Fig. 1).
When the scores of the randomized SYNTAX population
were divided into tertiles, the upper boundary of the lowest
tertile was 22 (low risk), the second tertile ranged from 23
to 32 (intermediate risk), and the lower boundary for the
highest tertile is≥33 (high risk).
The SXscore has since been consistently shown to
demonstrate poorer outcomes and to be an independent
predictor of major adverse cardiac events (MACE) in the
high tertile group of risk for PCI with both multivessel and
LMS disease at up to 5 years of follow-up [15]. This is
maintained even with next-generation drug-eluting stents.
For example, Wykrzykowska et al. [16]d e m o n s t r a t e di nt h e
LEADERS all-comers trial a higher rate of myocardial
infarction (MI), target vessel revascularization, and MACE in
highest tertile of the SXscore Of note is that within this study
approximately 30% of the high SXscore risk tertile had 3VD
compared with only 10% in the low SXscore risk tertile.
Within the CABG population, the SXscore however
appears to have little predictive value for outcome. This is
likely due to the simple fact that the bypass is anastomosed
distal to the severe coronary disease, regardless of the
complexity, provided there are suitable graftable targets [17].
Functional SYNTAX Score
The FAME study first established that by utilizing fractional
flow reserve (FFR) measurements to determine the func-
tional significance of individual coronary lesions and guide
subsequent coronary intervention, that this leads to a
potential prognostic impact when compared with angio-
graphic guidance alone [18–20]. Consequently, by incorpo-
rating FFR measurements into the SXscore to form the
416 Curr Cardiol Rep (2011) 13:415–423Table 1 Summary of a selection of established and contemporary risk models categorized by anatomical, clinical, or combined types for the
assessment of risk in patients proposing to undergo revascularization




Anatomical- and functional-based scores
ACC/AHA lesion
classification
0 11 (per lesion) Predrug-elutingstentera:predictiveofangiographicsuccessofPCIandprognosticeffectonearlyandlate
clinical outcomes. Conflicting results in the drug-eluting stent era [10–13]
Myocardial Jeopardy
scores
Encompasses severity of coronary artery lesions and the volume of myocardium subtended by the
stenosis (ie, amount of myocardium at risk)








a PCI: APPROACH lesion score most predictive
CABG: Duke Jeopardy score most predictive
SYNTAX score
(SXscore)
0 11 (per lesion) Quantifies coronary artery disease complexity by tertiles of SXscore: more events (death, MACCE) in
the higher tertiles of risk at up to 3 years follow-up [2￿, 7]
Functional SYNTAX
score
0 11 (per lesion) FFR-guided SXscore calculation improved prognostic ability of the SXscore: death/MI, MACE at
1 year [21]
Clinical-based scores
Parsonnet score 14 0 Operative mortality after open heart surgery [36]
New Mayo Clinic risk
score
7 0 Procedural death and MACE for PCI [24]
In-hospital death with CABG or PCI [25]
EuroSCORE (additive
or logistic)
17 0 Operative mortality for all forms of cardiothoracic surgery [5, 6]
Evidence for predicting death or MACCE in high-risk tertiles for PCI [27–29￿, 30–32]
NCDR CathPCI risk
score




3 0 Operative mortality in elective cardiac operations [33, 34￿]
Predictor of cardiac death and MI at 1 year after PCI; inferior to the SXscore at predicting overall
MACE and the risk of repeat revascularization [35]
Northern New
England score
8 0 In-hospital mortality after CABG [53]
New Y ork CABG risk
index
10 0 In-hospital mortality after CABG [54]
Combined (anatomical and clinical based) risk scores
Society of Thoracic
Surgery score





Predictors of in-hospital MACE after PCI or CABG [58]
Procedural: 1
b
New Y ork PCI risk
score
8 1 In-hospital death for PCI procedures [59]
Parsonnet+SYNTAX
score
14 11 MACCE and death at a median follow-up of 973 days (PCI) and 1298 days (CABG) [38]
Clinical SYNTAX
score
3 11 (per lesion) MACCE and death after PCI at 5 years follow-up [41]
NERS 17 Angiographic:
33
6-month cardiac death and cumulative MACE after unprotected LMS PCI [44]
Procedural: 4
c
Global Risk 17 11 (per lesion) Death and MACCE after unprotected LMS PCI [43, 46]
a Number of segments of myocardium at risk
bNumber of stents.
cNeed of IABP , two-stent technique, IVUS guidance
ACC American college of cardiology, AHA American heart association, APPROACH Alberta provincial project for outcome assessment in
coronary heart disease, BARI bypass angioplasty revascularization investigation, CABG coronary artery bypass grafting, EuroSCORE European
system for cardiac operative risk evaluation, IABP intra-aortic balloon pump, IVUS intravascular ultrasound, LMS left main stem, MACE major
adverse cardiac events, MACCE major adverse cardiac and cerebrovascular events, MI myocardial infarction, NCDR national cardiovascular data
registry, NERS new risk classification score, PCI percutaneous coronary intervention, SYNTAX synergy between percutaneous coronary
intervention with taxus and cardiac surgery
Curr Cardiol Rep (2011) 13:415–423 417recently dubbed, Functional SYNTAX score, it was shown
in a retrospective subanalysis of almost 500 patients with
multivessel disease from the FFR-guided arm of FAME,
that this improved the risk stratification of patients when
compared with the conventional angiographic-based
SXscore [21]. The primary benefit appeared in reclassifying
a significant proportion of the higher-risk groups into
lower-risk categories while still maintaining a significantly
higher event rate (death/MI and MACE at 1 year) in the
high-risk groups. However, the study did not include LMS
disease, and from a practical perspective, even if validated
in larger prospective populations, is limited by the more
invasive nature of the procedure.
One of the criticisms of the FAME study was that
quantitative coronary angiography (QCA) was not used to
assess vessel size and instead was reliant on visual estimation
[22]. Visual assessment is well known to be associated with
poor reproducibility and often overestimates lesion signifi-
cance [10]. If QCA had been used to assess vessel size, then
the potential benefit seen in favor of FFR may have been
less. The practice of visual assessment of vessel/lesion size is
however representative of real-life practice and was also the
basis of how the SXscores were calculated within the
SYNTAX study. Novel techniques to potentially simplify
the generation of the newly developed Functional SYNTAX
score include the use of noninvasive computed tomographic
angiography that allows for the simultaneous assessment of
anatomy and the measurement of the hemodynamic signifi-
canceoflesions(Heartflow,RedwoodCity,California,USA).
Limitations
The progressive development of anatomical-based risk
scores culminating in the Functional SYNTAX score has
undoubtedly improved the performance of these risk
models in terms of stratification for the individual patient.
However, the limiting factors are the inevitable variability
in coronary angiogram assessment if visual assessment is
used to assess the vessel/lesion size [7, 23]. With the
potential use of the Functional SYNTAX score this problem
may be circumvented, especially if a noninvasive assess-
ment of the Functional SYNTAX score is developed as
mentioned. The other limiting factors are that no clinical
variables are used, which in themselves are less subjective
than some angiographic variables; consequently, important
prognostic information may potentially be missing that may
aid in risk stratifying these patients further.
Clinical-Based Risk Scores
The main advantages of clinical-based scores are that they
are potentially easier to perform and less subjective
compared with purely anatomical-based scores that require
interpretation of the coronary angiogram. They can also be
performed relatively quickly and often at bedside if
necessary.
EuroSCORE
The EuroSCORE is an established risk model, which utilizes
17 clinical variables within cardiothoracic practice for predict-
ing operative mortality [5, 6, 26]. In use since 1999, the
model was derived from almost 20,000 consecutive patients
from 128 hospitals in eight European countries. The additive
model assigns an individual score to 17 clinical variables and
has been validated in many populations around the world.
These studies have consistently demonstrated that among
Fig. 1 The distribution of the SYNTAX score in the randomized and
registry PCI and CABG populations from the SYNTAX trial. Note how
the distributions for both the PCI and CABG registries are shifted to the
right, whereas for the randomized population both curves are almost
superimposable on each other [1, 7]. CABG coronary artery bypass
grafting, PCI percutaneous coronary intervention, RCT randomized
controlled trial, SYNTAX Synergy Between Percutaneous Coronary
Intervention with TAXUS and Cardiac Surgery. (Reprinted from
EuroIntervention; Serruys PW , Onuma Y ,G a r gS ,e ta l . :A s s e s s m e n to f
the SYNTAX score in the Syntax study. Copyright 2009, with
permission from Europa Edition); [7]
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ranges from 1 to 2, intermediate-risk tertile from 3 to 5, and a
high-risk tertile of 6+ (Table 2). The subsequently developed
logistic EuroSCORE allows for a more accurate risk
prediction within the CABG cohort, in particular for the
high-risk patient in which the additive model was found to
lead to a potential underestimation of risk.
Kim et al. [27] first demonstrated that the high-risk
tertile of the EuroSCORE was an independent predictor of
death/MI after unprotected LMS intervention with
sirolimus-eluting stents. Subsequently, Romagnoli et al.
[28] applied the additive EuroSCORE to predict in-hospital
mortality in 1173 consecutive patients undergoing PCI in a
single high-volume center and correlated the higher-risk
tertiles of the EuroSCORE with in-hospital mortality. This
included patients who had undergone unprotected LMS PCI
[28]. In addition, several studies have since all identified
the additive EuroSCORE as an independent predictor of
major adverse cardiac and cerebrovascular events
(MACCE) among patients with unprotected LMS PCI at
up to 4 years of follow-up [27, 29￿, 30–32]. Only one study
has examined the logistic EuroSCORE in PCI patients;
however, little differences were found in stratifying risk
when compared with the additive EuroSCORE [28].
ACEF Score
Ranucci et al. [33, 34￿] demonstrated in a relatively simple
risk model consisting of only three clinical variables—age,
preoperative serum creatinine value, and left ventricular
ejection fraction—a risk model for assessing operative
mortality risk in elective cardiac operations. Of note is that
despite the simplicity of the model, its clinical performance
appeared to be equivalent to either the additive or the
logistic EuroSCOREs [33, 34￿].
The ACEF score is calculated using the formula:
ACEF¼ Age Ejectionfraction % ðÞ = ½  þ 1 if creatinine > 2mg dL = Þ ð  : ½
From this score, a mortality risk can be calculated from a
graphical relationship of the score with an operative risk or
an equation [33, 34￿].
The ACEF model was recently applied to PCI patients
from the all-comers LEADERS population at 1-year
follow-up [35]. Despite the ACEF score being demon-
strated to be superior to the SXscore alone as a predictor
of cardiac death and MI after PCI, the ACEF score was
found to be inferior to the SXscore at predicting overall
MACE and the risk of repeat revascularization. This
reflects the observation that anatomical and clinical
variables appear to be a necessary requirement for a
comprehensive risk model in predicting clinical outcomes
with PCI.
Limitations
The main limitations of the clinical-based risk scores alone
are predominantly related to the lack of anatomical
variables which in themselves may carry additional prog-
nostic information, such as the SYNTAX score as previ-
ously discussed.
Combined (Anatomical and Clinical) Based Risk Scores
SYNTAX Score and the Parsonnet Score
By combining the Parsonnet score, an operative risk score
published in 1989 consisting of 14 clinical variables [36],
with the SXscore, it has been shown that this may
potentially improve the performance of the SXscore alone.
In 2005, V algimigli et al. [37] demonstated that the
Parsonnet score was an independent predictor of MACE
after LMS intervention from the Rotterdam RESEARCH
and T-SEARCH registries. More recently, Chakravarty et al.
[38] demonstrated that by adding the Parsonnet score as a
covariate to the SXscore, this improved the ability of the
score in predicting MACCE after LMS PCI.
Clinical SYNTAX Score
The underlying rationale for the Clinical SYNTAX Score
was to combine, by multiplication, the SXscore and a
variant of the ACEF score (modified ACEF score), of
which the latter had proven to be comparable to the
EuroSCORE in elective CABG patients as previously
described [33, 34￿]. The modified ACEF score was used
instead of ACEF score in this model as it had previously
been demonstrated that this potentially allowed for a more
accurate assessment of the underlying renal function and
had subsequently improved the accuracy of cardiac predic-
t i o nm o d e l ss u c ha st h eE u r o S C O R E[ 39–41]. The
modified ACEF score is calculated by using the formula:
age/ejection fraction+1 point for every 10-ml/min reduc-
tion in creatinine clearance below 60 ml/min/1.73 m
2 (up to
a maximum of 6 points).
This model was applied to the ARTS II population
treated with sirolimus-eluting stents for multivessel coro-
nary artery disease by our group [41, 42]. By dividing the
calculated Clinical SYNTAX scores into tertiles of risk, it
was demonstrated that the risk model for predicting
outcomes for MACCE and death at 5 years was superior
to the SXscore or modified ACEF scores alone. One of the
limiting factors of the Clinical SYNTAX score was that
despite being able to predict events accurately in the high-
risk tertile, the risk model was unable to discriminate
between the end points for the low- and intermediate-risk
Curr Cardiol Rep (2011) 13:415–423 419tertiles [41]. This was also recently demonstrated within a
registry of patients undergoing left main PCI [43].
New Risk Classification Score
The New Risk Classification Score (NERS) [44] is a risk
model developed to predict outcomes for unprotected LMS
PCI from four centers in China (n=260). Reflecting the long
period over which this registry was performed (~ 10 years),
the patients included had either bare-metal or drug-eluting
stent implantation. The model was subsequently validated in
a different consecutive group of patients within the same
registry all treated with drug-eluting stents (n=337).
This risk model consists of 54 variables (17 clinical, 4
procedural, and 33 angiographic features). A substantially
higher c-statistic was evident for the NERS compared with
the SXscore (NERS: 0.89 vs SXscore: 0.69), indicating
that it had an excellent discriminatory ability. When the
NERS score was separated into two groups of risk (high
and low) and clinical outcomes assessed, the high-risk
group was demonstrated to be significantly more predic-
tive of MACE compared with the intermediate or high
SXscore tertiles.
In the low-risk NERS group, outcomes were similar to
the low SXscore group, suggesting at least from this study
that anatomical variables alone may be sufficient to be
predict outcomes in the low-risk group. However, patient
comorbidity was significantly less prevalent in the NERS
patient population compared with the all-comers SYNTAX
population [1, 3], the latter of which was designed to
overcome many of the limitations/bias selections inherent in
small registries. V alidation of the NERS risk model in a much
larger,randomizedpopulationofpatientsisthereforerequired.
Global Risk
The SYNTAX trial established a complex interaction
between the EuroSCORE and the SXscore. The need to
combine the angiographic and clinical scores into a single
approach consequently became evident [45].
The Global Risk approach (Table 2) aims to potentially
combine established historically accepted clinical variables
from the EuroSCORE [5, 6] with anatomical variables from
the SXscore [7, 9, 14] to allow for a Global Risk
assessment for patients proposing to undergo revasculari-
zation with PCI [45]. By adopting this approach, the same
risk model could potentially be used by the Heart Team to
appropriately risk stratify patients proposing to undergo
PCI or CABG. This may potentially increase the number of
patients who could safely and efficaciously be treated with
PCI compared to the use of the SYNTAX score alone.
In variants of this model, one group has previously
demonstrated the potential of the Global Risk model to
enhance risk stratification among patients who underwent
LMS PCI from a single-center registry [43, 46]. A major
criticism of their approach has been the lack of consistency
in their application of the Global Risk model. The range of
scores within each tertile of risk for the EuroSCORE and
SXscores has been established as described earlier [5–7, 9,
14]. Yet in the two publications using the Global Risk
approach by the same group [43, 46], a different range of
scores for the tertiles of risk for the EuroSCORE and
SXscores has been used [46, 47]. It is the authors’ opinions
that the established range of scores for the tertiles of risk for
the EuroSCORE and SXscore (Fig. 1) should be maintained
to allow the application of the Global Risk model across
surgical and PCI populations, and importantly allow for a
consistency in the ranges of scores that will make
application of the model by other groups possible and
ultimately may allow validation of this risk model in the
future, should this risk model prove feasible. Further study
into the concept of a Global Risk approach utilizing the
EuroSCORE and SXscores with ranges of risks based on
consistently defined values for the EuroSCORE and
SXscore tertiles are forthcoming.
Risk/Benefit Analysis
Undoubtedly, both PCI and CABG allow for an improvement
in the quality of life for patients. However, one of the main
drawbacks of using contemporary risk models for both PCI
and CABG is that the role of the individual patient, their
personal preferences, and perception of risk may be under-
estimated.To address thisissue,the novel concept ofa clinical
model that balances the risks and benefits of the proposed
revascularization procedure has recently emerged [48￿].
Table 2 The concept of the Global Risk approach, combining the
additive EuroSCORE and SYNTAX score (SXscore) using historically
defined tertiles of risk for the EuroSCORE [5, 26] and the SYNTAX


























EuroSCORE European system for cardiac operative risk evaluation,
SYNTAX synergy between percutaneous coronary intervention with
taxus and cardiac surgery
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within their professional/personal lives may be vital, and they
would thus potentially be more prepared to accept the longer-
term risks associated with PCI—namely increased revascu-
larization—to remain at their present functional state, in
exchange for being free from the short-term morbidity
associated with CABG. The latter being predominantly
related to the intrinsically more invasive nature of the CABG
procedure (eg, thoracotomy and vein harvesting and subse-
quent sternotomy and leg pain) [49, 50]. However, individual
patients may value this risk/benefit tradeoff differently. For
some, exchanging the increased risk of repeat PCI or CABG
to obtain short-term pain relief and a rapid return to full
mobility will be acceptable, whereas others may prefer to
endure short-term pain to obtain a higher probability of
avoiding a subsequent revascularization. Patients may also
prefer to risk undergoing multiple PCI procedures rather than
a single CABG, or they may prefer to avoid the risk of
requiring CABG subsequent to PCI and instead have CABG
initially. Consequently, from the patient’s perspective, the
balance between these conflicting considerations appears to
play a crucial role in the identification of the preferred
revascularization strategy.
Federspiel et al. [48￿] recently applied this concept to the
ARTS I population, by quantifying the tradeoff between the
risks and benefits of PCI versus CABG for patients with
multivessel disease [42]. Although this study was per-
formed on study data that were over 10 years old, in a
population who had implantation of bare-metal stents, the
results were nevertheless supportive of this concept and
allowed for the first time a quantification of a level of risk
that a patient would be willing to accept to maintain their
present functional state. Data from the SYNTAX and other
trials on this very concept to reflect more contemporary
practice with drug-eluting stents are forthcoming.
Conclusions
It would appear that a combination of clinical and
anatomical variables are required for an effective, clinically
useful risk model for patients with complex coronary artery
disease proposing to undergo multivessel PCI. Ideally this
model would be simple to calculate and could be rapidly
performed at the bedside. However, the need to include
detailed anatomical assessments appears evident, such as
the incorporation of the SXscore. The pragmatic approach
appears in developing and refining a risk model that
incorporates both elements in as simple a way as possible.
Concepts such as the noninvasive calculation of the
Functional SYNTAX score may serve to streamline this
process and the concept of patient-empowered risk/benefit
tradeoff are potential further areas for research.
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